DOCSLIB.ORG

Recente Informatie

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recente Informatie RECENTE INFORMATIE WIJZIGINGEN AAN HET GECOMMENTARIEERD GENEESMIDDELENREPERTORIUM (oktober - november 2008) De uitleg over het symbool ¼ staat op bladzijde 7 van het Gecommentarieerd Geneesmiddelenrepertorium 2008. Blz. SPECIALITEITEN OP BASIS VAN EEN NIEUW ACTIEF BESTANDDEEL 122 TOVIAZ (Pfizer) ¼ fesoterodinefumaraat compr. (vertraagde vrijst.) 28 x 4 mg R/ 51,62 ¬ 84 x 4 mg R/ 109,92 ¬ 28 x 8 mg R/ 56,81 ¬ 84 x 8 mg R/ 123,09 ¬ Posol. 4 à 8 mg p.d. in 1 gift Anticholinerg spasmolyticum voorgesteld voor de behandeling van “urge”-incontinentie (aandrangincontinentie) 325 ISENTRESS (MSD) ¼ raltegravir compr. 60 x 400 mg R/ a¼ 897,30 ¬ Integrase-inhibitor, antiretroviraal middel van een nieuwe klasse, te gebruiken samen met andere antiretrovirale middelen SPECIALITEITEN OP BASIS VAN EEN REEDS GECOMMERCIALISEERD ACTIEF BESTANDDEEL 80 WILATE (Octapharma) factor VIII 450 IE factor von Willebrand – RCof 400 IE flacon i.v. – inf. poeder + 5 ml solv. R/ a¼ 420,95 ¬ factor VIII 900 IE factor von Willebrand – RCof 800 IE flacon i.v. – inf. poeder + 10 ml solv. R/ a¼ 832,21 ¬ (S.D., behandeling door warmte) 81 OCTAPLEX (Octapharma) factor II 220 à 760 IE factor VII 180 à 480 IE factor IX 500 IE factor X 360 à 600 IE proteïne C 140 à 620 IE proteïne S 140 à 640 IE flacon i.v. poeder + 20 ml solv. H.G. (S.D., nanofiltratie) 102 CYNACTIL (Tilman) artisjokextract (droog) 200 mg rozemarijnextract (droog) 125 mg caps. 28 7,80 ¬ 105 MOTILIUM (Impexeco) domperidon compr. 30 x 10 mg 8,28 ¬ 132 ECOSAL (Teva) salbutamol Easi-Breathe (aërosol) 200 doses 100 µg/dosis R/ 11,00 ¬ 1 134 ECOBEC (Teva) beclometasondipropionaat Easi-Breathe (aërosol) 200 doses 250 µg/dosis R/ b² 24,23 ¬ 172 DONACOM (Madaus) ¼ glucosaminehemisulfaat gran. (zakjes.) 30 x 1178 mg R/ 18,00 ¬ 90 x 1178 mg R/ 39,95 ¬ Posol. 1,18 g p.d. in 1 gift 221 LAMOTRIGINE TEVA (Teva) lamotrigine compr. (disp.) 30 x 25 mg R/ a¼ 10,01 ¬ 90 x 50 mg R/ a¼ 40,19 ¬ 90 x 100 mg R/ a¼ 62,43 ¬ 30 x 200 mg R/ a¼ 50,92 ¬ 254 ELEONOR (Sandoz) ethinylestradiol 0,02 mg levonorgestrel 0,1 mg compr. 3 x 21 R/ 13,02 ¬ 6 x 21 R/ 20,83 ¬ 13 x 21 R/ 37,27 ¬ 260 BICALUTAMIDE MYLAN (Mylan) bicalutamide compr. 28 x 50 mg R/ a¼ 101,33 ¬ 289 DOCCEFACLO (Docpharma) cefaclor caps. 15 x 500 mg R/ b 11,34 ¬ sir. 100 ml 250 mg/5 ml R/ b 8,32 ¬ Specialiteit opnieuw beschikbaar 334 INFLEXAL V (Crucell) oppervlakte-antigenen van influenzavirus (op basis van virussen gekweekt op cellen van kippenembryo’s) spuitamp. i.m. – s.c. 1 x 0,5 ml R/ cs¼ 10,84 ¬ (bevat neomycine en polymyxine B) 335 HAVRIX (Impexeco) geïnactiveerd hepatitis A-virus (kweek op humane cellen) spuitamp. i.m. 1 x 1.440 E.Elisa/1 ml R/ 45,66 ¬ (bevat aluminium, neomycine en formaldehyde) 356 ADVAGRAF (Astellas) tacrolimus caps. (vertraagde vrijst.) 50 x 0,5 mg R/ a 92,40 ¬ 100 x 1 mg R/ a 266,24 ¬ 50 x 5 mg R/ a 617,44 ¬ 372 VITA-CALCEA (Ratiopharm) calciumcarbonaat 1,5 g colecalciferol 400 IE bruiscompr. 60 15,27 ¬ (600 mg Ca++) 416 OTIPAX (Biodiphar) lidocaïnehydrochloride oordruppels 15 ml 10 mg/ml R/ 5,85 ¬ NIEUWE VORMEN EN ANDERE WIJZIGINGEN 42 BISOPROLOL MYLAN (Mylan) compr. (deelb.) 84 x 5 mg R/ b 11,50 ¬ 84 x 10 mg R/ b 20,20 ¬ 2 51 PERINDOPRIL SANDOZ (Sandoz) compr. (deelb.) 60 x 4 mg R/ b 20,82 ¬ 100 x 4 mg R/ b 30,31 ¬ 57 CO-BISOPROLOL MYLAN (Mylan) bisoprololfumaraat 5 mg hydrochloorthiazide 12,5 mg compr. (deelb.) 84 R/ b 11,50 ¬ bisoprololfumaraat 10 mg hydrochloorthiazide 25 mg compr. (deelb.) 84 R/ b 20,20 ¬ 68 NOOTROPIL (UCB) lees oploss. (oraal) 150 ml 200 mg/ml R/ 15,01 ¬ 80 OCTANATE (Octapharma) flacon i.v. 250 IE + 5 ml solv. lees R/ a¼ 238,16 ¬ 500 IE + 10 ml solv. lees R/ a¼ 466,64 ¬ 1.000 IE + 10 ml solv. lees R/ a¼ 923,60 ¬ 81 BENEFIX (Wyeth) flacon inf. 500 IE + 5 ml spuit solv. R/ a¼ 387,74 ¬ 1.000 IE + 5 ml spuit solv. R/ a¼ 765,80 ¬ 2.000 IE + 5 ml spuit solv. R/ a¼ 1521,92 ¬ 88 DOC SIMVASTATINE (Docpharma) Naamswijziging (vroeger Docsimvasta) 109 LACTULOSE TEVA (Teva) sir. 300 ml 3,1 g/5 ml 6,50 ¬ 123 ALFUZOSINE MYLAN (Mylan) compr. (vertraagde vrijst.) 56 x 5 mg R/ 17,95 ¬ 149 AVAMYS (GSK) neusspray 120 doses 27,5 µg/dosis lees R/ b § 14,66 ¬ 159 NEVRINE CODEINE (Sterop) lees coffeïne 50 mg codeïnefosfaathemihydraat 30 mg paracetamol 500 mg compr. 20 R/ 3,77 ¬ Formulewijziging 162 DICLOFENAC EG (Eurogenerics) compr. (maagsapresist.) 30 x 50 mg R/ b 5,65 ¬ 176 MATRIFEN (Nycomed) transdermaal systeem 2 x 12 µg/u R/ b 9,44 ¬ 2 x 25 µg/u R/ b 13,30 ¬ DOC TRAMADOL (Docpharma) druppels 5 x 10 ml 100 mg/ml R/ b 17,67 ¬ 190 SEDANXIO (Tilman) caps. 100 x 200 mg 15,70 ¬ 203 PAROXETINE EG (Eurogenerics) compr. (deelb.) 56 x 30 mg R/ b 36,87 ¬ PAROXETINE SANDOZ (Sandoz) compr. (deelb.) 28 x 30 mg R/ b 26,87 ¬ 60 x 30 mg R/ b 39,29 ¬ 100 x 30 mg R/ b 59,00 ¬ 3 228 AERIUS (Schering-Plough) compr. 50 x 5 mg R/ cs 27,20 ¬ oploss. (oraal) 150 ml 2,5 mg/5 ml R/ cs 8,93 ¬ 260 BICALUTAMIDE EG (Eurogenerics) compr. 100 x 50 mg R/ a¼ 270,91 ¬ 269 NOVO MIX 70 (Novo Nordisk) insuline aspart (vloeibaar) 70 E insuline aspart (protamine) 30 E/ml patroon s.c. Penfill 5 x 3 ml R/ a¼ 40,94 ¬ 272 AVANDIA (GSK) compr. 112 x 4 mg R/ a¼ 102,54 ¬ 112 x 8 mg R/ a¼ 154,96 ¬ 274 AVANDAMET (GSK) metforminehydrochloride 1 g rosiglitazon 2 mg compr. 112 R/ a¼ 60,63 ¬ metforminehydrochloride 1 g rosiglitazon 4 mg compr. 112 R/ a¼ 87,56 ¬ 277 OMNITROPE (Sandoz) patroon s.c. 5 x 10 mg/1,5 ml R/ a¼b¼ 1156,42 ¬ 320 CYMEVENE (Roche) lees flacon inf. 1 x 500 mg poeder H.G. 364 NAVELBINE (Pierre Fabre Medicament) caps. 1 x 20 mg H.G. 1 x 30 mg H.G. 377 FOLINATE EG (Eurogenerics) Naamswijziging (vroeger Folina Cell) 445 FOSAVANCE (MSD) alendroninezuur 70 mg colecalciferol 5.600 IE compr. 12 R/ b¼ 70,94 ¬ PAMIDRONATE EG (Eurogenerics) Naamswijziging (vroeger Pamidro Cell) NOTA 132-137 Terugbetaling van de geneesmiddelen gebruikt bij astma en COPD Vanaf 1 november 2008 worden alle terugbetaalbare verpakkingen (met uitzondering van Ventolin compr., sir. en amp. i.m. – s.c.) van de klassen 4.1.1. tot 4.1.8. van het Gecommentarieerd Geneesmiddelenrepertorium terugbetaald (terugbetalingscategorie b) volgens hoofdstuk II, d.w.z. zonder voorafgaand akkoord van de adviserend-geneesheer maar met een a posteriori controle. Het betreft volgende specialiteiten. - Airomir, Docsalbuta, Ventolin - Foradil, Novolizer Formoterol, Oxis - Serevent - Atrovent, Spiriva - Combivent, Duovent - Beclophar, Qvar - Budesonide Easyhaler Sandoz, Miflonide, Novolizer Budesonide, Pulmicort, Flixotide - Inuvair, Seretide, Symbicort - Euphyllin, Theolair, Xanthium - Cromoglycate Sodique EG, Lomudal - Singulair, Accolate, Resma 4 SCHRAPPINGEN 29 Nysconitrine 213 Tremblex 43 Carvedilol Sandoz 228 Aerius sir. compr (deelb.) 14 x 6,25 mg 249 Farlutal 52 Quinapril Mylan compr. 30 x 20 mg 298 Amukin flacon Lyophilised i.m. – i.v. 57 Selozide 321 Rebetol caps. 84 x 200 mg 88 Simvastatine Mylan compr. 140 x 200 mg 102 Vibtil 363 Vepesid amp. inf. 109 Lactulose Teva sir. 200 ml Velbe 142 Acetylcysteine Mylan gran. (zakjes) Oncovin 158 Asodal 364 Paxene 159 Perdolan Compositum supp. Kind 377 Befact 163 Clinoril 395 Srilane 176 Ionsys 409 Atropine Minims 177 Tramadol Teva 420 Synthol compr. Instant (smelttablet) 436 Acomplia* 202 Citalopram Mylan compr. (deelb.) 438 Nicorette 30 x 40 mg kauwgommen 30 x 2 mg 60 x 40 mg kauwgommen Mint 30 x 2 mg * Zie bericht van 24/10/2008 in de rubriek “Goed om weten” op onze website, en Folia december 2008 5 .
Load more

Recommended publications
  • Réglementation De La Pharmacie
    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
    [Show full text]
  • Case No COMP/M.2192 - 3* SMITHKLINE BEECHAM / BLOCK DRUG
    EN Case No COMP/M.2192 - 3* SMITHKLINE BEECHAM / BLOCK DRUG Only the English text is available and authentic. REGULATION (EEC) No 4064/89 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 11/01/2001 Also available in the CELEX database Document No 301M2192 Office for Official Publications of the European Communities L-2985 Luxembourg COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 11.01.2001 SG(2000)D/285020 In the published version of this decision, some PUBLIC VERSION information has been omitted pursuant to Article 17(2) of Council Regulation (EEC) No 4064/89 concerning non-disclosure of business secrets and other confidential information. The omissions are MERGER PROCEDURE shown thus […]. Where possible the information ARTICLE 6(1)(b) DECISION omitted has been replaced by ranges of figures or a general description. To the notifying party Dear Sir/Madam, Subject: Case No COMP/M.2192 – SmithKline Beecham/Block Drug Notification of 17.11.2000 pursuant to Article 4 of Council Regulation No 4064/89 1. On 17 November, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EEC) No 4064/89 (“the Merger Regulation”), by which the UK company, SmithKline Beecham plc (“SB”) notified its intention to acquire sole control over the US company, Block Drug Company Inc. (“Block Drug”), through purchase of shares. 2. Following examination of the notification, the Commission has concluded that the notified operation falls within the scope of the said Council Regulation and does not raise serious doubts as to its compatibility with the common market and the EEA agreement.
    [Show full text]
  • Principaux Changements Dans Le Répertoire
    INFORMATIONS RECENTES MODIFICATIONS AU REPERTOIRE COMMENTE DES MEDICAMENTS (octobre - novembre 2008) Vous trouverez l’explication du symbole ¼ à la page 7 du Répertoire Commenté des Médicaments 2008. Page SPECIALITES A BASE D’UN NOUVEAU PRINCIPE ACTIF 122 TOVIAZ (Pfizer) ¼ fésotérodine fumarate compr. (lib. prolongée) 28 x 4 mg R/ 51,62 ¬ 84 x 4 mg R/ 109,92 ¬ 28 x 8 mg R/ 56,81 ¬ 84 x 8 mg R/ 123,09 ¬ Posol. 4 à 8 mg p.j. en 1 prise Spasmolytique anticholinergique proposé dans le traitement de l’incontinence d’urgence 325 ISENTRESS (MSD) ¼ raltégravir compr. 60 x 400 mg R/ a¼ 897,30 ¬ Inhibiteur d’intégrase, nouvelle classe d’antirétroviral à utiliser en association à d’autres antirétroviraux SPECIALITES A BASE D'UN PRINCIPE ACTIF DEJA COMMERCIALISE 80 WILATE (Octapharma) facteur VIII 450 UI facteur von Willebrand – RCof 400 UI flacon i.v. – perf. poudre + 5 ml solv. R/ a¼ 420,95 ¬ facteur VIII 900 UI facteur von Willebrand – RCof 800 UI flacon i.v. – perf. poudre + 10 ml solv. R/ a¼ 832,21 ¬ (S.D., traitement par la chaleur) 81 OCTAPLEX (Octapharma) facteur II 220 à 760 UI facteur VII 180 à 480 UI facteur IX 500 UI facteur X 360 à 600 UI protéine C 140 à 620 UI protéine S 140 à 640 UI flacon i.v. poudre + 20 ml solv. U.H. (S.D., nanofiltration) 102 CYNACTIL (Tilman) artichaut extrait sec 200 mg romarin extrait sec 125 mg caps. 28 7,80 ¬ 105 MOTILIUM (Impexeco) dompéridone compr. 30 x 10 mg 8,28 ¬ 132 ECOSAL (Teva) salbutamol Easi-Breathe (aérosol) 200 doses 100 µg/dose R/ 11,00 ¬ 1 134 ECOBEC (Teva) béclométasone dipropionate Easi-Breathe (aérosol) 200 doses 250 µg/dose R/ b² 24,23 ¬ 172 DONACOM (Madaus) ¼ glucosamine (hémisulfate) gran.
    [Show full text]
  • Case M.9274 - GLAXOSMITHKLINE / PFIZER CONSUMER HEALTHCARE BUSINESS
    EUROPEAN COMMISSION DG Competition Case M.9274 - GLAXOSMITHKLINE / PFIZER CONSUMER HEALTHCARE BUSINESS Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Article 6(1)(b) in conjunction with Art 6(2) Date: 10/07/2019 In electronic form on the EUR-Lex website under document number 32019M9274 EUROPEAN COMMISSION Brussels, 10.7.2019 C(2019) 5366 final PUBLIC VERSION In the published version of this decision, some information has been omitted pursuant to Article 17(2) of Council Regulation (EC) No 139/2004 concerning non-disclosure of business secrets and other confidential information. The omissions are shown thus […]. Where possible the information omitted has been replaced by ranges of figures or a general description. To the notifying party Subject: Case M.9274 - GLAXOSMITHKLINE / PFIZER CONSUMER HEALTHCARE BUSINESS Commission decision pursuant to Article 6(1)(b) in conjunction with Article 6(2) of Council Regulation No 139/20041 and Article 57 of the Agreement on the European Economic Area2 Dear Sir or Madam, (1) On 17 May 2019, the European Commission (“the Commission”) received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation by which GlaxoSmithKline plc. (“GSK”, United Kingdom) will acquire sole control over the consumer health business of Pfizer Inc. (“Pfizer”, United States), hereinafter referred to as “Pfizer CH” (“the Transaction”). GSK is referred to as “the Notifying Party” and, together with Pfizer CH, as “the Parties”. 1 OJ L 24, 29.1.2004, page 1 (the 'Merger Regulation'). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ('TFEU') has introduced certain changes, such as the replacement of 'Community' by 'Union' and 'common market' by 'internal market'.
    [Show full text]
  • Formulaire Therapeutique Tunisien
    REPUBLIQUE TUNISIENNE MINISTERE DE LA SANTE PUBLIQUE FORMULAIRE THERAPEUTIQUE TUNISIEN Direction de la Pharmacie et du Médicament Centre collaborateur de l’OMS en matière d’enregistrement 2ème et de réglementation pharmaceutique Edition http://www.dpm.tn Ce document a été élaboré par l’équipe de la Direction de la Pharmacie et du Médicament suivante : Dr Kamel Iddir, Pr Nadia Fenina, Mr Mohamed Imed Lassoued, Mme Myriam Najjar, Mr Raouf Zmerli, Mlle Samira Zeghal, Mr Youssef Khedher, Mr Mokhtar Mzoughi, Mme Soumaya Miled Hlaili, Mlle Zeineb Ben Othman, Mlle Besma Ben Fredj, Mr Hassen Mokaadi, Mme Jamila Khrouf, Mme Yomna Ben Lamine, Mme Emna Zribi Triki. Comité scientifique de supervision : Pr Saida Ben Becher, Hôpital d’enfants, Mme Nahed Ennaifer, Pharmacien Hospitalier, Mme Myriam Guerfali, Pharmacien Hospitalier, Pr Taoufik Nacef, Conseil National de l’Ordre des Médecins, Mr Ali Naas, Pharmacien d’officine, Mr Abdelkrim Hamrouni, Conseil National de l’Ordre des Pharmaciens, Pr Slah Eddine Sellami, Hôpital Charles Nicolle, Mme Amel Ben Rachid, Pharmacien d’officine, Pr Mohamed Lakhal, Centre National de Pharmacovigilance, Mr Nabil Saïd, Pharmacien Industriel, Pr Bouaouina Noureddine, Hôpital Farhat Hached Sousse, Pr Mahmoud Khrouf, Médecin de libre pratique. Ce document a été revu par Pr Amor Toumi de l’Organisation Mondiale de la Santé. Remerciements : La Direction de la Pharmacie et du Médicament remercie particulièrement l’Organisation Mondiale de la Santé pour sa contribution à l’édition de cet ouvrage et à sa réalisation. 1 INTRODUCTION I - OMS C'est avec beaucoup de plaisir que j'assume l'honneur qui m'échoit d'introduire cet ouvrage.
    [Show full text]
  • Top 100 Global Consumer Packaged Goods Companies
    Top 100 global consumer packaged goods companies (non food/beverage**) Company Name Headquarters 2008 Sales 1. Procter & Gamble Cincinnati, OH $65 Billion 2. Unilever United Kingdom $27.3 Billion 3. L'Oréal Clichy, France $25.8 Billion 4. Kimberly-Clark Corp. Dallas, TX $19.4 Billion 5. Colgate-Palmolive New York, NY $15.33 Billion 6. Reckitt Benckiser Berkshire, United Kingdom $11.2 Billion 7. Avon Products, Inc. New York, NY $10.69 Billion 8. Henkel Düsseldorf, Germany $10.5 Billion 9. Kao Tokyo, Japan $10.5 Billion 10. S.C. Johnson Racine, WI $8 Billion 11. Estee Lauder New York, NY $7.91 Billion 12. Beiersdorf Hamburg, Germany $7.5 Billion 13. Johnson & Johnson New Brunswick, NJ $7.2 Billion 14. Shiseido Tokyo, Japan $6.9 Billion 15. Amway Ada, MI $6.5 Billion 16. Alcon Laboratories, Inc. Huneberg, Switzerland $6.29 Billion 17. Ecolab St. Paul, MN $6.14 Billion 18. Allergan Irvine, CA $4.33 Billion 19. LVMH Paris, France $4.2 Billion 20. Coty New York, NY $4 Billion 21. Liz Claiborne New York, NY $4* Billion 22. Wyeth Consumer Healthcare Madison, NJ $4* Billion 23. Bayer Consumer Health Morristown, NJ $3.95 Billion 24. Nestle Health Care Nutrition Glendale, CA $3.9 Billion 25. Chanel Neuilly sur Seine, France $3.3 Billion 26. Johnson Diversey Sturtevant, WI $3.3 Billion 27. Novartis Consumer Healthcare-OTC Parsippany, NJ $3 Billion 28. Scotts Miracle-Gro Co. Marysville, OH $2.98 Billion 29. Bausch & Lomb Rochester, NY $2.92 Billion Return to List Top 100 global consumer packaged goods companies (non food/beverage**) Company Name Headquarters 2008 Sales 30.
    [Show full text]
  • Global Innovation in Emerging Economies
    Global Innovation in Emerging Economies In recent decades, there have been signifi cant changes in the way corporate innovation is performed. They include changes in the innovation process, fl ex- ibility to outsource innovation activities, and most importantly, the location of innovation. There are mainly two new trends: First, location of globally strategic R&D by the multinational corporations (MNCs) in some developing countries; second, more recently, some companies from the emerging econo- mies have also started performing R&D to develop products and services for global markets. These trends are occurring in a dynamic business environment that consists of mutually reinforcing economic and technological changes. These trends have managerial implications for companies and policy implica- tions for the emerging economies where such R&D is performed, as well as for the industrialized home countries of the companies. Further, innovative products and services resulting from R&D activities in emerging economies seem to better address the needs of consumers at the bottom-of-the-pyramid in other developing countries. Global Innovation in Emerging Economies examines the dynamics of the globalization processes and the emergence of new locations for innova- tion and its implications. Exploring twenty in-depth case studies of MNCs, local companies, and research institutes/universities based in Brazil, China, India, and South Africa (the so-called BRICS Group), Prasada Reddy devel- ops a conceptual framework of the evolution of globalization of corporate R&D. This unique books addresses many issues including the context for location of global R&D in emerging economies by MNCs and the driving forces behind this trend, performance of global R&D by companies from emerging economies, and national and corporate implications of these new trends for innovation systems.
    [Show full text]
  • Alli Heads OTC Brand Cull at Glaxosmithkline
    OTC29-04-11p1&24FIN.qxd 28/4/11 07:19 Page 1 29 April 2011 COMPANY NEWS 3 Valeant sets Cephalon 3 Alli heads OTC brand a May deadline J&J’s OTC sales drop 4 by a quarter in US cull at GlaxoSmithKline Atrium strikes deal 5 in Canada Omega encouraged by 6 laxoSmithKline Consumer Healthcare’s Brand Category opening quarter Gflagship weight-loss medicine Alli is one Novartis OTC sprints 7 of a number of OTC brands put up for sale Abtei VMS* ahead of market by the company because it has not got the Alli Weight management Bart Becht to leave 8 marketing clout to make them successful. Beano Gastrointestinal Reckitt Benckiser In a shock move,the firm has admitted that BC Analgesic North American sales rise 9 Alli – the first medicine to be switched cen- Beconase Respiratory tract boosts turnover at Boiron trally to non-prescription status in Europe and Debrox Excess ear wax Blackmores believes Asia 10 with launch sales of £110 million (C124 mil- Dequadin Cough/cold holds key to future growth lion) in 15 weeks in the US – could do better Ecotrin Analgesic Caffetin coaxes Alkaloid forward 10 in different hands. FiberChoice Dietary supplement GlaxoSmithKline has now turned its back GENERAL NEWS 11 on the orlistat-based weight-loss medicine in Goody’sAnalgesic a move to refocus its Consumer Healthcare op- Granufink Urological Consumer group demands 11 eration. Yet as recently as June 2007, the com- Lactacyd Feminine hygiene ban on Alli pany invested enormous sums to launch the Libenar Respiratory tract US FDA targets global supply chain 12 brand in the US – after paying Roche US$100 Nytol Sleep aid FDA takes action over 13 million (C68 million) plus royalty and mile- Phillips MOM Gastrointestinal MRSA claims in the US stone payments for the US OTC rights alone Solpadeine Analgesic MARKETING NEWS 14 in 2004 (OTC bulletin,30 July 2004, page 1).
    [Show full text]
  • Here's the a to Z of Every Major Brand in Our Portfolio*
    GSK Consumer Healthcare is home to an impressive set of global brands that millions of consumers, retailers, experts and shoppers worldwide know and love. Here’s the A to Z of every major brand in our portfolio*: *Information on previously announced brand divestments is included at the end of this list. Aquafresh provides dental care and feel good protection for kids and adults with a range of toothpastes, toothbrushes and on-the-move oral care products. Major markets: Global (branded Binaca in Spain, Odol in Czech Republic, Odol-med3 in Germany). Abreva is a range of specialist cold sore products providing a complete regimen from rescue to daily care. Major markets: USA, Canada, Puerto Rico. Acne-Aid helps with the management of acne and any condition where greasy skin predominates. Major markets: Asia, Brazil, Middle East. Actifed is a combination decongestant and antihistamine. Major markets: Southern Europe, Africa, Middle East. Actiprotec is a disposable flu mask with an antiviral coating. Major markets: North America, North and West Europe. Alikal provides relief from stomach discomfort and headache symptoms. Major markets: South America. alli is the only FDA-approved weight loss product available without a prescription. Major markets: US, Europe. Ansolar is a high protection, non-greasy and hypoallergenic product that comes in a gel and lotion form, to protect the skin against sun. Major markets: Latina. Astringosol is a mouthwash that helps fight plaque and infection. Major markets: Mexico, Asia. Babix is a nappy rash cream for babies. Major market: Brazil. Bactroban is an acne treatment (China) or available for the treatment of skin infections and prevention of infection in minor cuts and wounds (Canada).
    [Show full text]
  • Guide Des Médicaments D'officine 2019, Vous Pouvez Acheter Le Livre Papier
    GUIDE DES MÉDICAMENTS D'OFFICINE Avertissement Malgré tout le soin apporté à la réalisation de ce document, des erreurs sont toujours possibles. Les informations publiées dans cet ouvrage ne sauraient engager la responsabilité de l’auteur. Tous les noms commerciaux et marques cités dans ce livre sont la propriété de leurs détenteurs respectifs. N’hésitez pas à envoyer vos remarques ou suggestions à l'auteur : [email protected] Notes de version Chaque année, de nombreuses modifications sont apportées au Guide des Médicaments d'Officine pour le maintenir à jour, le compléter et l'améliorer. Désormais, nous publions les notes de version des dernières éditions en toute fin de livre afin que le lecteur puisse prendre connaissance des changements apportés au fil des années. © 2019 Maximilien DEBERLY. Tous droits réservés. ISBN 978-0-244-69910-9 ____________ Édition 2019 Maximilien DEBERLY Notes de l'auteur Année après année, le succès du Guide des Médicaments d'Officine se confirme. Le but de ce livre est simple : offrir aux étudiants en pharmacie et aux élèves préparateurs un support entièrement consacré aux médicaments. Le médicament est le cœur du métier des préparateurs et des pharmaciens. Pourtant, nous sommes nombreux à trouver que nos études ne nous forment pas assez à la dispensation des traitements, même si je connais les efforts réalisés par les CFA et les facultés dans ce sens. Étudiants et apprentis, pour aborder sereinement le comptoir et renvoyer une image de compétence aux patients, vous devez être à l'aise avec les classes thérapeutiques, connaître les médicaments qui les composent et les éléments utiles à la dispensation (principales indications, contre-indications, principaux effets indésirables...).
    [Show full text]
  • GSK Consumer Healthcare (SMIBC) Rating : Buy | 6062 Target : | 7193 Target Period : 12-15 Months Health Consciousness, Capex to Drive Growth Potential Upside : 19%
    Initiating Coverage July 13, 2015 Rating Matrix GSK Consumer Healthcare (SMIBC) Rating : Buy | 6062 Target : | 7193 Target Period : 12-15 months Health consciousness, capex to drive growth Potential Upside : 19% GSK Consumer Healthcare (GCHL) is one of the largest malt beverage YoY Growth (%) companies in India with strong brands like Horlicks, Boost, Maltova & Viva. (YoY Growth) FY14 FY15 FY16E FY17E Over the years, it has been a leader in the malt beverage market with a Net Sales 52.7 (11.5) 10.9 15.3 EBITDA 52.2 (16.3) 20.6 17.4 combined volume market share of 66%. The company is also involved in Net Profit 54.5 (13.5) 18.4 17.0 selling & distributing some OTC products like Crocin, Eno, Sensodyne, EPS (Rs) 54.5 (13.5) 18.4 17.0 Iodex & Breathe Right of GlaxoSmithKline Asia Pvt Ltd and GlaxoSmithKline * FY14 numbers are for 15 months Pharmaceuticals and generates auxiliary income. The brand equity of Current & target multiple Horlicks & Boost, rapid pace of growth of OTC products & introduction of FY14 FY15 FY16E FY17E newer OTC products has led to revenue and PAT CAGR of 17.5% & 20.2%, P/E 37.8 43.7 36.9 31.5 respectively, in CY09-FY15. We believe the malt beverage industry in India Target P/E 42.4 49.0 41.4 35.4 is poised to witness swift growth led by higher disposable income, increase EV / EBITDA 27.1 31.8 26.3 22.4 in rural penetration & premiumisation. We expect the company will witness P/BV 14.1 12.1 10.3 8.7 a revenue & PAT CAGR of 15.3% & 17.7%, respectively, in FY15-17E.
    [Show full text]